High-Dose Heparin in Pregnant Women: Implications for Neuraxial Analgesia Safety

Beth Israel Lahey Health > 37
Beth Israel Deaconess Medical Center

Kelly Li, BS, Philip E Hess, MD, Yunping Li, MD*, Amnon A Berger, MD, PhD* Department of Anesthesia, Critical Care, and Pain Medicine at BIDMC | Harvard Medical School



Background and Hypothesis





American Society of Regional Anesthesia

Anticoagulation Guidelines 2018:

12-hour delay between **high-dose subcutaneous heparin** (SQH >15,000 IU/day) and **neuraxial block placement.**

Hypothesis:

Pregnant patients receiving **high-dose SQH** can safely undergo **neuraxial analgesia (NA)** with appropriate monitoring.

Objectives:

- 1. Determine time to PTT normalization in parturients on high-dose SQH.
- 2. Evaluate the **safety of neuraxial procedures** in this population.

High-Dose Heparin in Pregnant Women: Implications for Neuraxial Analgesia Safety Study Design and Methods



Kelly Li, BS, Philip E Hess, MD, Yunping Li, MD*, Amnon A Berger, MD, PhD*
Department of Anesthesia, Critical Care, and Pain Medicine at BIDMC | Harvard Medical School

Study design

- Retrospective cohort study
- Single tertiary hospital
- January 2017 May 2022

Population


Pregnant patients on **high-dose SQH** (>15,000 IU/day or >7,500 IU BID) at the **time of admission for delivery.**

Data collection

Heparin dosing, serial PTTs, NA administration details, hemorrhage outcomes, potential confounders

PTT < 40 sec considered safe. Statistical significance: p < 0.05.

Inclusion flowchart



High-Dose Heparin in Pregnant Women: Implications for Neuraxial Analgesia Safety Results

Beth Israel Lahey Health

Kelly Li, BS, Philip E Hess, MD, Yunping Li, MD*, Amnon A Berger, MD, PhD*
Department of Anesthesia, Critical Care, and Pain Medicine at BIDMC | Harvard Medical School

Cohort characteristics:

Age 21 - 41 yrs


Nulliparous 52%

Indications
VTE 50
Hypercoagulopathy 18
CVA 2

Overview

56 patients had safe PTTs upon first measurement **9 patients** had prolonged PTTs upon first measurement

| Variable | Mean ± SD | Range |
|--------------------------------|-----------------|----------------|
| PTT Normalization Time | 26.0 ± 16.9 hrs | 7.9 - 61.4 hrs |
| Time from SQH to Block | 26.4 ± 13.0 hrs | 9.0 - 61.9 hrs |
| % with Safe PTT at Block | 65/65 (100%) | |
| Cervical Dilation before Block | 3.9 cm | 1 - 10 cm |



Key findings

- Total Daily Heparin Dose is the only statistically significant predictor (r = 0.19, p = 0.038)
- BMI, Age, Cr, and Gestational Age are NOT significant.
- At time of NA placement, 0 patients had PTT >40s (3 patients had PTT > 35s).
- No spinal/epidural hematomas or major morbidity.

High-Dose Heparin in Pregnant Women: Implications for Neuraxial Analgesia Safety Discussion and Conclusions



Kelly Li, BS, Philip E Hess, MD, Yunping Li, MD*, Amnon A Berger, MD, PhD*
Department of Anesthesia, Critical Care, and Pain Medicine at BIDMC | Harvard Medical School

Question: Can pregnant patients receiving **high-dose SQH** safely undergo **neuraxial analgesia**?



Discussion

- Most parturients on high-dose SQH have safe PTT levels upon admission for labor.
- All patients received an anesthesia consult, with interdisciplinary care by OB Anesthesiology, Obstetrics, and Hematology.
- **Weakly significant relationship** between total heparin dose and PTT normalization time.
- No hematomas or severe complications observed.
- Scheduled induction of labor helps improve safety.

Limitations

- Small cohort of patients, missing some comorbidity data
- Scarcity of patients on very high doses (>20,000 IU/day)
- Infrequency and irregularity of PTT testing

Citations

Horlocker TT, et al. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: ASRA Guidelines, 2018.